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Abstract 
An analysis of the important intermolecular interactions of the active pharmaceutical 
ingredient (API) lovastatin which contribute to the surface chemistry and attachment 
energy morphology is presented. The analysis is supported by a recent 
redetermination of the single crystal structure (orthorhombic space group P212121) 
and targets the understanding and potential control of the morphology of lovastatin, 
which tends to crystallise in a needle-like morphology, where the aspect ratio varies 
depending on the nature of the solvent. The lattice energy was calculated to be -
38.79 kcal mol-1 with a small contribution of -2.73 kcal mol-1 from electrostatic 
interactions. The lattice structure is significantly stabilised by the 
hexahydronaphthalene ring of the molecule, which contributes 43.39 % of the lattice 
energy. Synthon analysis shows that the dominant intermolecular interaction within 
the lattice structure of lovastatin is found to be along the a crystallographic axis, 
associated with a dispersive stacking interaction due to the close packing of two 
hexahydronaphthalene rings resulting in a total energy of -6.46 kcal mol-1. The 
attachment energy morphology correlates well with the observed crystal morphology 
which exhibits a needle-like habit dominated by {0 1 1}, {0 2 0}, {0 0 2} and {1 0 1} 
crystal forms. The needle capping faces are found to contain the short stacks of 
hexahydronaphthalene rings where the strong intermolecular synthon is found to 
contribute positively to the attachment energy and hence growth at this surface. This 
dominant intermolecular synthon is concluded to be the major cause of enhanced 
growth along the crystallographic a axis leading to the formation of a needle-like 
morphology. A habit modification strategy is discussed which uses recrystallization 
from a-polar solvents to reduce the effective growth rate at the needle capping 
surfaces. This is supported through experimental data which shows that crystals 
 3 
 
obtained from crystallisation in hexane and methyl-cyclohexane have significantly 
reduced aspect ratios in comparison to those grown from methanol and ethyl acetate 
solutions. Crystals obtained from nitromethane solutions were found to have a very 
large reduction in aspect ratio to a prismatic morphology, critically with no polymorph 
change. 
Introduction 
Mevinolinic acid or lovastatin belongs to the statin class of drug compounds, one of 
the most widely prescribed drug classes worldwide for the treatment of 
hypercholesterolemia. Lovastatin targets and inhibits the enzyme 
hydroxymethylglutaryl coenzyme A reductase (HMG-Co A), which plays a key role in 
initiating the synthesis of cholesterol, hence lovastatin hinders the biosynthesis 
pathway of cholesterol. Lovastatin is generally isolated through a chemical synthesis 
or biosynthesis fermentation route, where the product is then isolated and purified 
through a re-crystallization strategy, generally from alcohol or acetone/water mixes1.  
Lovastatin has been the target of many physicochemical screening studies within the 
literature due to its importance as an industrial active pharmaceutical ingredient 
(API). The solid state physicochemical properties of lovastatin have been studied 
utilising thermal analysis methods; the melting point was found to be 445 K and 
where the crystalline material undergoes amorphization when recrystallized with the 
preservative butylhydroxyanisole2. The solubility of lovastatin was measured in a 
number of solvent systems; namely in a series of homologous acetates3, alcohols4 
and also in acetone/water mixtures5, where the solubility is lower in polar solvents 
due to the hydrophobic nature of the compound. Additionally the nucleation kinetics 
of lovastatin have been determined using turbidometric techniques in ethanol, 
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methanol and acetone solutions; where the mechanism of nucleation was found to 
be instantaneous in ethanol and acetone and progressive in methanol4. 
Due to the hydrophobicity of lovastatin, the drug falls into the second class of drug 
compounds under the Biopharmaceutics Classification System (BCS), 6 7 where the 
drug exhibits high permeability and low solubility, the molecular structure and 
material descriptors for lovastatin are provided in S1 of the ESI. As a result the drug 
is impacted by poor bioavailability and hence efforts to improve the absorption of the 
drug have included nanoparticle synthesis and implementation of lipid based carrier 
systems8, 9.  Lovastatin also exhibits a needle-like morphology when recrystallized 
from solution, which can lead to problematic downstream processing issues such as 
poor particle flow, problematic filtration and particle breakage10.  
The physicochemical and mechanical properties of crystalline materials can be 
calculated using molecular modelling tools through atom-atom summation methods 
which utilize atomistic forcefields to calculate intermolecular interaction strength and 
directionality11 12 13 14 15 16 17. Much progress has been made in this field, particularly 
when applying these ‘synthonic engineering’ methodologies to organic molecular 
crystals18 19, where particle morphology20 21, solvent-surface interactions22, surface 
chemistry23 and excipient-API interactions24 are some of the emerging areas of 
interest. Nguyen25 et al recently applied a synthonic engineering approach to 
understand the interfacial stability of the crystallographic faces of ibuprofen and 
rationalise the various aspect ratio crystals obtained from differing solution 
environments during crystal growth. Rosbottom26 and co-workers have also utilised 
synthonic engineering by applying a grid-based surface searching methodology27 28 
29 30 to explain the anisotropic wettability of the crystal surfaces of ibuprofen.  
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This paper aims to utilise the approaches of synthonic engineering and molecular 
modelling discussed above to further understand the bulk crystal chemistry and 
surface chemistry of lovastatin in relation to its observed needle-like morphology. 
Additionally it aims to quantify the extrinsic (surface terminated) synthon contribution 
to the attachment of molecules at the growing crystal surfaces. This is part of an 
overall strategy to effect the habit modification of this material to mitigate the impact 
of the observed needle-like morphology of lovastatin by providing a fundamental 
molecular understanding of both the crystallographic structure and the nature of the 
interactions of the solute with its surrounding solution environment.  
Materials and Methods  
Chemicals 
Lovastatin was used as supplied by through the EPSRC Future Continuous 
Manufacturing and Advanced Crystallisation (CMAC) Research Hub, and originally 
purchased through Molekula. Ethyl acetate HPLC >99.95%, methanol HPLC 
99.61%, hexane HPLC 99.9% purity was used as supplied by Fisher. Toluene 
reagent grade >99.7%, methyl cyclohexane anhydrous >99% was used as supplied 
by Sigma Aldrich. 
Experimental Methodology 
Single Crystal X-ray Diffraction 
Single crystals of lovastatin (colourless needles) were obtained by slow evaporation 
from saturated ethyl acetate, methanol, methyl cyclo-hexane, toluene, hexane and 
nitromethane solutions at 25 °C. Single crystal X-ray diffraction data were recorded 
at the University of Bath, on a dual source Rigaku Oxford Diffraction Gemini A Ultra 
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diffractometer, equipped with an Atlas CCD detector and an Oxford Cryosystems 
Cryojet-XL liquid nitrogen flow device for temperature control. Data collection, 
indexing and integration procedures were performed using the Rigaku Oxford 
Diffraction software CrysAlis Pro31. Using Olex232, the structure was solved by dual 
space methods using ShelXT33 and refined by Least Squares methods using 
ShelXL34. Hydrogen atoms were positioned geometrically and refined using a riding 
model. The hydrogen atom isotropic displacement parameters were fixed to Uiso(H) = 
1.5 x (for CH3) or Uiso(H) = 1.2 x (for CH2 and CH) the Ueq of the parent atom. The 
structure is included in the Cambridge Structural Databases as a CSD 
Communication with CSD refcode CEKBEZ0135.  
Powder X-ray Diffraction 
Powder x-ray diffraction was used for polymorph characterisation of the prepared 
lovastatin crystals from slow solvent evaporation. The powder samples were ground 
to a powder using a mortar and pestle then mounted on a single cut silicon crystal 
powder holder and scanned using a Bruker36 D8 advanced X-ray diffractometer 
using Cu Kα radiation and a germanium primary monochromator in Bragg-Brentano 
reflection geometry. The step size was 0.033 2θ with a step time of 0.7 s/step over a 
2θ range of 2-39.8 2θ. The detector used was a Vantec-1 position sensitive detector.
 
Modelling Methodology 
Visualisation of the crystal structure was carried out using the Cambridge 
Crystallographic Data Centre’s (CCDC) Mercury software37. The conformational 
analysis of lovastatin (CEKBEZ01)35 was performed using the Forcite module in 
Accelrys Material Studio38 where the geometry of a single lovastatin molecule of the 
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major disorder component, was optimised with respect to the potential energy 
surface to minimise the total energy of the structure. The PCFF39 40 41  forcefield was 
used and the atomic charges were calculated using Gasteiger42 43, the energy 
convergence was calculated using the SMART algorithm. The geometry of this gas 
phase optimised molecule of lovastatin was then compared to the conformation of 
the molecule in the crystal structure.   
The lattice, slice and attachment energies were calculated using an atom-atom 
summation method using Habit9844 45  using the Momany46 potential where the 
atomistic charges were calculated within Mopac47. Habit98 builds a series of unit 
cells which expand outward from a central unit cell, the intermolecular interaction 
between a central molecule and all others within an expanding sphere, the radius of 
which was set as 1 – 30 Å to ensure lattice energy convergence, are calculated. The 
resulting lattice energy was partitioned into the slice and attachment energy based 
on Equation 148. 
𝐸𝑐𝑟 = 𝐸𝑠𝑙 + 𝐸𝑎𝑡𝑡          (1) 
𝜀ℎ𝑘𝑙 =
𝐸𝑠𝑙
𝐸𝑐𝑟
           (2) 
Where Ecr is the lattice energy, Esl is the slice energy and Eatt is the attachment 
energy. The important morphological faces were selected based upon the Bravais, 
Friedel, Donnay and Harker (BFDH) rule49 50 51 which states the surfaces with lowest 
surface energy will be those with the greatest inter-planar d-spacing and were 
chosen using the Morphology tool with Materials Studios. The predicted morphology 
was calculated using the top 10 crystal planes sorted by the highest d-spacing where 
the attachment energy of those faces was calculated and the attachment energy was 
approximated to a surface-specific growth rate. The morphology was then 
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reconstructed using a Wulff plot using SHAPE52 53. The surface anisotropy factors54 
55, εhkl, which describe the termination of the synthons at a specific habit face, were 
calculated using Equation 2 and expressed as a percentage. The plane rugosity of 
the crystal faces were calculated based on the average route mean square 
displacement of the atomic centres of the molecules in the unit cell along the growth 
normal within the d-spacing of the crystallographic planes. The plane rugosity 
provides a simple measure of the variation in height for a given crystallographic 
plane and hence provides a description of the smoothness for a given crystal plane 
at an atomic level. The intermolecular synthons were analysed and ranked by their 
total intermolecular energy contribution to the overall lattice energy of lovastatin 
following a methodology previously reported by Rosbottom et al17. 
Results 
Single Crystal Structure Determination  
The single crystal structure of lovastatin (CSD refcode CEKBEZ) was first published 
by Sato et al. in 1984 and was determined from room temperature X-ray diffraction 
data.56 The data presented in this paper are a modern redetermination of the 
structure at low temperature (150 K), confirming that the overall structure of 
lovastatin remains largely unchanged on cooling, the crystal structure refinement 
data of lovastatin is provided in S2 of the ESI. No structural phase transition is 
observed on cooling, with the same P212121 space group retained at 150 K and 
slightly reduced unit cell parameters, as is in-keeping with thermal contraction on 
cooling (overall decrease in unit cell volume = c.a. 2%). An overlay of the two 
structures in the CSD software Mercury57 confirms that the molecular conformation is 
largely unchanged on cooling, with a RMS deviation of 0.0214 calculated between 
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the two structures (see ESI, S2 Figure 2). The key difference between the new 
structure and that published by Sato et al. is that disorder in the S-butanoate ester 
group was resolved at low temperature. The S-butanoate group is found to be 
disordered over two positions and was freely refined using standard PART 
instructions to determine a ratio of 57% of the major component and 43% of the 
minor component (see ESI S2 Figure 3). The conformation of the major component 
overlays well with the reported room temperature arrangement for this group (see 
ESI S2 Figure 2). Although no disorder was reported by Sato et al., analysis of their 
original structure data does show that the anisotropic displacement parameters 
(ADPs) for the S-butanoate chain are significantly larger than for the rest of the 
structure (for example, the reported ADP for the carbon atom of the terminal CH3 
group is c.a. 2 x larger than that of other CH3 groups in the structure).56 These 
observations indicate that the presence of disorder cannot be entirely ruled out in the 
room temperature structure, and are thus consistent with our own observations at 
low temperature. It should also be noted that the data quality is also remarkably 
improved in the 150 K redetermination, with a residual factor R1 = 3.17% in 
comparison to R1 = 8.2% for the original dataset. A reduction in data quality at room 
temperature is common,58 and hence may reasonably have prevented reliable 
refinement of any potential disorder in the structure collected in 1984. Given this 
comparison, we chose the 150 K redetermination as the basis for our molecular 
modelling calculations which were performed using the major component, however 
for clarity the methodology was repeated using the minor component where the data 
is comparable and the conclusions drawn from this analysis are in agreement; this is 
provided in S3 of the ESI. 
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Figure 1 a) the crystal structure of lovastatin viewed down the crystallographic c axis highlighting the 
close stacking of the hexahydronaphalene rings (red arrows) along the a axis and b) view down the 
crystallographic a axis highlighting the hydrogen bond between the S-butanoate ester group and the 
alcohol functionality   
 
 
Figure 1a) provides a view of the lovastatin crystal structure down the b axis which 
highlights the close packed nature of the hexahydronaphthalene rings which run 
down the short a axis of the crystal structure. The crystal structure contains one 
hydrogen bond between the alcohol functionality and the carbonyl of the S-butanoate 
ester group. These interactions form a broken chain which runs ~30° from plane 
normal down the crystallographic b axis. Additionally there is a notable short contact 
between the carbonyl group of the tetrahydropyran ring and an acidic proton on an 
adjacent tetrahydropyran ring which runs ~20° from plane normal to the 
crystallographic a axis, an enlarged view of this contact is provided in S4 of the ESI.  
Conformational Analysis 
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The calculated gas phase conformation of a lovastatin molecule is shown as yellow 
in Figure 2 and is overlaid for comparison to the conformation of the molecule in the 
asymmetric unit found in the crystal structure, coloured by atom type in Figure 2. The 
data shows that in general the conformation of the lovastatin molecule does not 
change dramatically when going from the gas phase to the crystal structure. This is 
particularly observable in the conformations of the hexahydronaphthalene and the S-
butanoate ester groups, which exhibit very little conformational change. The torsion 
around the carbon back bone highlighted as red T1 in View A, Figure 2 highlights 
this small change which only differs by ~1°, 172° - 171° when going from the gas 
phase to the crystalline phase. The tetrahydropyran ring group, however, does 
undergo some conformational rotation when going from the gas phase to the solid 
phase, where the ring is rotated ~ 23°, 154° – 177°, through torsion T2 highlighted in 
green in View B, Figure 2. The total energy of the molecule within the crystal 
structure was found to be -19.70 kcal mol-1 and the optimised gas phase molecule 
had a total energy of -20.82 kcal mol-1, which correlates well with a small 
conformational change. Overall this analysis is consistent with the material only 
having a single known polymorph; where the crystal structure conformation is 
already relatively close to the molecular free energy minima. 
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Figure 2 Conformational overlay of the gas phase optimised lovastatin molecule (yellow) and the 
molecule in the asymmetric unit of lovastatin (coloured by atom type) highlighting the conformational 
change of the tetrahydropyran ring through torsion 2 (T2 Green) 
Lattice Energy and Intermolecular Synthon Analysis 
The lattice energy of lovastatin converged at -38.79 kcal mol-1 where the electrostatic 
contribution converges at -2.73 kcal mol-1 at a maximum convergence distance of 30 
Å. The lattice energy and electrostatic contribution energy as a function of limiting 
radius are provided in Figure 3a), this shows that the lattice energy converges in two 
shell’s, the first at 6 – 9 Å and the second at 13 Å as shown in Figure 3b). The very 
low contribution to the lattice energy provided by electrostatic interactions is 
unsurprising considering the largely dispersive nature of the lovastatin molecule.  
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Figure 3 a) Convergence of the calculated lattice total energy as a function of limiting radius for 
lovastatin, also indicating the contribution made to this by the electrostatic interactions, b) the % 
contribution to the lattice energy as a function of convergence distance, indicating the three shells via 
which the lattice energy of lovastatin converges together with the number of molecules in the shell 
The lattice energy of lovastatin was further collapsed onto the asymmetric molecular 
unit to provide a quantitative analysis of the relative functional group contribution to 
stabilising the crystal lattice. Figure 4a) provides this quantitative breakdown onto the 
lovastatin molecule where the hexahydronaphthalene group (α) contributes 43.39 % 
of the lattice energy, indicating the importance of dispersive interactions within the 
lovastatin lattice structure. The tetrahydropyran functionality (β) contributes 29.42 % 
and the S-butanoate ester group (γ) contributes 27.24 %, interestingly the β group 
contains the acidic proton short contact between the carbonyl group of the 
tetrahydropyran ring and the protons of an adjacent tetrahydropyran ring. Whereas 
the γ group contains the long range H-bond (~2.0 Å) from the ester functionality, this 
highlights the subtle differences between the H-bonding component and the short 
contact component to the lattice energy where the acidic proton short contact seems 
to play a greater role in contributing to the stabilisation of the lattice structure. 
Figure 4b) summarises the top seven intermolecular synthons, ranked by 
intermolecular interaction energy, which contribute to the lattice energy of lovastatin, 
additionally Table 1 summarises the breakdown of these synthonic interactions into 
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attractive, repulsive, coulombic and total energy from the force field calculation. 
Synthon A provides the largest contribution to the lattice energy of lovastatin, -6.46 
kcal/mol and 33.31% of the total lattice energy, ~ 3.5 kcal/mol greater than synthon B 
which highlights the importance of this close packed interaction which is ~98% 
dominated by dispersive interactions between the hexahydronaphthalene groups as 
summarised in Table 1.  Synthons B and E contain a larger coulombic component, 
~20% and 26% contribution to the overall interaction respectively. This is due to the 
hydrogen bond between the alcohol proton and carbonyl oxygen in synthon B and 
the acidic proton short contact in synthon E as shown in Figure 4b). Synthons F and 
G provide a relatively small contribution to the overall crystal lattice energy with weak 
dispersive type interactions of -1.05 and -0.92  kcal/mol respectively. These seven 
synthons provide 93.06% of the total lattice energy of lovastatin and hence analysis 
of further intermolecular synthons was not carried out due to their low contribution to 
the overall lattice energy. 
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Figure 4 a) The percentage contribution to the lattice energy provided by the 3 functional groups of 
the lovastatin asymmetric unit, and the breakdown of each to dispersive and coulombic contribution to 
the total, b) The top seven intermolecular synthons which contribute to the lattice energy of lovastatin, 
ranked as a function of total interaction energy, Synthon A shows the breakdown of the total 
contribution of the three main functionality’s (as identified in a)) of the lovastatin molecule towards the 
overall intermolecular interaction energy together with the percentage contribution of the dispersive 
and coulombic components of those functionality’s 
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Table 1 The top seven intermolecular synthons which contribute to the lattice energy of lovastatin, 
ranked in order of total interaction energy, also provided is the contribution of each synthon to the 
total lattice energy and also the contributions in multiplicity of synthons to the surfaces present in the 
attachment energy morphology  
Synthon *Distance/Å 
Dispersive 
Total 
kcalmol
-1
 
Coulombic 
kcalmol
-1
 
Total 
kcalmol
-
1
 
% 
Contribution 
of Lattice 
Energy 
Contribution 
to 
Attachment 
Energy {0 1 1} 
Contribution 
to 
Attachment 
Energy {0 2 0} 
Contribution 
to 
Attachment 
Energy {1 0 1} 
A 5.89 -6.31 -0.16 -6.46 33.31 0 0 4 
B 11.11 -2.47 -0.50 -2.98 15.36 2 4 3 
C 10.35 -2.58 0.02 -2.56 13.20 2 4 1 
D 10.03 -2.04 -0.08 -2.12 10.93 2 4 2 
E 11.39 -1.45 -0.51 -1.96 10.11 2 4 2 
F 11.11 -0.92 -0.13 -1.05 5.41 2 0 2 
G 11.91 -0.90 -0.01 -0.92 4.74 2 0 2 
     
Total =  
93.06 %    
*Distance is calculated from the centre of gravity of the two molecules contributing to the 
intermolecular interaction 
The strongest intermolecular synthon, Synthon A, comprises of a close stacked 
interaction of the hexahydronaphthalene rings. Figure 4b) provides a schematic of 
Synthon A with the breakdown of the interaction energy onto the functional groups of 
lovastatin. This shows that the hexahydronaphthalene rings provide 54.66% of the 
interaction energy and the β and γ functional groups provide 23.40% and 21.52% 
respectively. Further to this, it was found that the components of this intermolecular 
interaction energy is dispersive in nature as highlighted by the breakdown of the 
energy into dispersive and coulombic components as highlighted in Table 1. 
Attachment Energy Morphology and Surface Chemistry 
The attachment energy morphology of lovastatin is provided in Figure 5 where the 
simulation yields a needle-like morphology dominated by {0 1 1}, {0 2 0}, {1 0 1} and 
{0 0 2} surfaces; where the {1 0 1} surfaces are the needle capping faces. The 
calculated attachment energy morphology is in reasonably good agreement with 
micrographs of lovastatin crystals grown from ethyl acetate and toluene solutions, 
 17 
 
shown in Figure 6 which present as needle-like crystallites albeit of a higher aspect 
ratio in comparison to the model morphology, a more detailed figure of the calculated 
attachment energy morphology is provided in S5 in the ESI.  
Table 2 summarises the slice, attachment energy and % surface saturation of the top 
10 BFDH face list of lovastatin, where the highlighted faces are those which are 
present in the calculated attachment energy morphology.  Interestingly the % surface 
saturation of the morphologically important surfaces, correlates well to the 
morphology, whereby the needle capping surfaces, {1 0 1}, have by far the lowest 
surface saturation, 30.21%, meaning growth in this direction would be favoured due 
to unsatisfied surface active intermolecular interactions. Conversely the slow growing 
{0 1 1} surface has the highest surface saturation, 66.69%, meaning growth is likely 
to be slower in this direction.  
Table 2 The calculated slice and attachment energies together with the % surface saturation of the 
top 10 BFDH face list for lovastatin, the major surfaces which appear in the calculated attachment 
energy morphology are highlighted 
Surface 
d 
Spacing 
/ Å 
Plane 
Rugosity 
/ Å 
Slice 
Energy / 
kcal mol
-1
 
Attachment 
Energy / kcal 
mol
-1
 
% Surface 
Saturation  
{0 1 1}  13.61 7.22 -25.87 -12.91 66.69 
{0 2 0} 8.66 5.88 -17.43 -21.35 44.93 
{1 0 1} 5.69 2.61 -11.72 -27.06 30.21 
{0 0 2} 10.99 6.09 -25.3 -13.48 65.22 
{0 1 2} 9.28 7.26 -23.75 -15.04 61.23 
{0 2 1} 8.06 6.69 -20.59 -18.2 53.08 
{0 1 3} 6.75 7.08 -23.71 -15.07 61.12 
{0 3 1} 5.59 6.44 -15.38 -23.41 39.65 
{0 2 3} 5.6 7.34 -23.71 -15.07 61.12 
{1 1 0} 5.6 3.41 -11.83 -26.95 30.50 
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The overall contribution of the top five intermolecular synthons, presented in Figure 
4, to the attachment energy of the {0 1 1}, {0 2 0} and {1 0 1} surfaces was calculated 
to assess the relative importance to the growth of these faces. This analysis is 
summarised in Table 1 where the multiplicity of each synthon is presented. This 
analysis shows that, interestingly, the needle capping {1 0 1} surface is the only 
morphological surface to contain synthon A as an extrinsic growth synthon. This 
correlates well with the observation that the morphology is extended down the a axis 
through this surface. Conversely the larger, slower growing {0 1 1} surface has no 
contribution from synthon A to its attachment energy and only has the lower energy 
synthons B, C, D and E with a multiplicity of 2, as extrinsic synthons.  
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Figure 5 Attachment energy morphology of lovastatin together with a visualisation of the surface 
chemistry of the morphologically important faces; {0 1 1}, {0 2 0} and {1 0 1} 
 
A visualisation of the surface chemistry for the {0 1 1}, {0 2 0} and {1 0 1} surfaces of 
lovastatin is provided in Figure 5. This indicates the closed packed nature of the {1 0 
1} needle capping surface and shows the relative availability of the 
hexahydronaphthalene rings at the surface which can provide stacking interactions 
to form the energetically favourable synthon A, which was highlighted in the previous 
analysis, and contributes to the attachment energy at this surface. Additionally the 
calculated plane rugosity (Table 2) of the {1 0 1} surface was found to be 2.61 Å 
which is low relative to the {0 1 1} and {0 2 0} surfaces. This could provide a more 
favourable growth environment, whereby de-solvation of the surface followed by 
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solute integration is to some extent less rate limited by the de-solvation step due to 
solvent trapping at the surface for example. Conversely the {0 1 1} and {0 2 0} 
surfaces have significantly higher calculated plane rugosity than the needle capping 
surface, which could impact de-solvation; where the channels trap solvent and hence 
decrease the rate of de-solvation and effectively decrease the growth rate at these 
surfaces relative to the needle capping surface. 
Synthonic and Surface Chemistry Analysis in Relation to the Needle 
Morphology of Lovastatin 
This analysis has indicated the importance of Synthon A, not only in contributing to 
the stabilisation of the lattice structure of lovastatin but also to the attachment energy 
as an extrinsic synthon on the needle capping {1 0 1} surface. The combination of a 
highly favourable dispersive stacking interaction between the two 
hexahydronaphthalene groups, the low calculated {1 0 1} plane rugosity and the 
availability of the hexahydronaphthalene groups at the capping surface are the likely 
cause of the formation of a  needle-like morphology due to faster crystal growth 
along the crystallographic a axis of lovastatin.  
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Figure 6 Micrographs of lovastatin crystals grown by slow solvent evaporation from, methanol (aspect 
ratio 118.0), ethyl acetate (aspect ratio 28.0), toluene (aspect ratio 21.7), methyl cyclohexane (aspect 
ratio 12.5), hexane (aspect ratio 4.8) and nitromethane solutions (aspect ratio 2.6), the approximate 
aspect ratio of the crystals were calculated by the ratio of the approximate length and width of the 
crystals 
The identification of Synthon A, not only as an important possible growth synthon, 
but also as an extrinsic synthon at the needle capping face, leads to the postulation 
of a crystallisation strategy to hinder or at least reduce the aspect ratio of the crystals 
through selective binding of the hexahydronaphthalene rings to hinder formation of 
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Synthon A. Micrographs of lovastatin crystals obtained from slow solvent evaporation 
in some non-polar solvents are provided in Figure 6. This highlights that in methyl 
cyclohexane, toluene, hexane and nitromethane solutions, the crystallites recovered 
had a significantly lower aspect ratio when compared to those grown in polar protic 
or polar a-protic solvents such as methanol and ethyl acetate. This is likely due to 
selectively binding of the a-polar component of the lovastatin molecule which would 
effectively decrease the de-solvation rate of the molecule at the 
hexahydronaphthalene group in the solution state, hindering the formation of 
Synthon A and also decrease the de-solvation rate of the {1 0 1} capping face 
relative to the side and top faces. This reduction in relative growth rate would likely 
decrease the aspect ratio to a more equant morphology.  
Nitromethane provides an interesting result as this solvent considerably reduces the 
aspect ratio of the lovastatin crystals to a prismatic-like morphology. The crystals 
obtained were analysed for polymorph changes, where powder x-ray diffraction 
showed the crystals to be the same crystal structure and hence no polymorph 
change or solvate formation had taken place, this data is provided in S6 of the ESI. 
The cause of this dramatic reduction in needle-like morphology is likely to be the 
prevention of Synthon A formation and the reduction of the growth rate on the needle 
capping face. This dramatic habit modification has also been shown for the case of 
p-aminobenzoic acid (PABA), where the needle-like alpha form can be reduced to a 
significantly more prismatic crystal habit through recrystallization from nitromethane 
solutions. This was found to be caused by interaction of nitromethane with the 
benzene ring of PABA and hence disrupting an important π-π stacking interaction 
which causes the needle-like morphology in the material. This is also likely the case 
for lovastatin, where the nitromethane could preferentially bind to the 
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hexahydronaphthalene ring system, probably through the unsaturated carbon atoms, 
and hence prevent Synthon A formation.  
The effect of ‘blocking’ Synthon A using solvation could also be similarly achieved 
through additive addition using the same principle. Additives such as poly-aromatic 
or poly-cyclic hydrocarbons e.g. naphthalene, could have the same effect by 
blocking Synthon A and also through disruption of the molecular recognition at the {1 
0 1} capping surface, reducing the effective growth rate.  
Conclusions 
A molecular modelling analysis of the intrinsic and extrinsic synthons of the API 
lovastatin in relation to its bulk and surface properties has been presented to 
rationalise the materials’ observed needle-like morphology. The synthonic analysis 
revealed a strong intermolecular interaction in the bulk structure which consisted of a 
close packed stacking interaction of two hexahydronaphthalene rings. This 
intermolecular interaction was found to be ~ 3.5 kcal mol-1 more energetically 
favourable than the second strongest synthonic interaction in the bulk structure. 
Additionally the hexahydronaphthalene ring of lovastatin was found to contribute 
43.39 % of the calculated lattice energy of the material, where 99.83% of this was 
found to be of a dispersive nature.  
The calculated attachment energy morphological model correlated reasonably well 
with the experimental morphology observed for crystals grown from ethyl acetate 
solutions, and was dominated by {0 1 1}, {0 2 0}, {1 0 1} and {0 0 2} surfaces.  
Analysis of the surface chemistry of the habit faces revealed that the {1 0 1} needle 
capping face was under-saturated with respect to its extrinsic synthons, where the 
surface saturation was calculated as 30.21%, compared to 66.69 % and 44.93 % for 
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the {0 1 1} and the {0 2 0} surfaces respectively. The {1 0 1} needle capping face 
also was found to have a lower plane rugosity, 2.61 Å, compared to 5.88 Å and 7.22 
Å for the {0 2 0} and {0 1 1} faces respectively. The analysis of the surface chemistry 
revealed that critically, Synthon A contributes positively to the attachment energy of 
the {1 0 1} capping surface, and does not contribute to the attachment energy of 
either the {0 2 0} and {0 1 1} faces. Hence it was concluded that Synthon A is the 
major cause for the formation of a needle-like morphology in lovastatin down the 
crystallographic a axis and a recrystallization strategy using a-protic or a-polar 
solvents or additives could be used as habit modifiers for this material to reduce the 
aspect ratio of the crystals. 
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List of Symbols 
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Ecr   Lattice energy / kcal / mol 
Esl   Slice energy / kcal / mol 
Eatt   Attachment energy / kcal / mol 
εhkl   Anisotropy factor 
Rint   Merging residual factor (crystallography): 
∑|𝐹𝑜
2−𝐹𝑜
2(𝑚𝑒𝑎𝑛)| 
∑[𝐹𝑜
2]
 
Rsigma   Signal-to-noise residual factor (crystallography): 
∑[𝜎𝐹𝑜
2]
∑[𝐹𝑜
2]
 
R1   Conventional residual factor (crystallography): 
∑||𝐹𝑜|−|𝐹𝑐||
∑|𝐹𝑜|
 
wR2   Weighted residual factor (crystallography): √
∑ 𝑤(|𝐹𝑜|2− |𝐹𝑐|2)2
∑ 𝑤|𝐹𝑜|2
 
ρcalc   Calculated density (crystallography) 
Ueq   Equivalent isotropic atomic displacement parameter 
Uiso   Isotropic atomic displacement parameter 
Z   Number of formula units within the crystallographic unit cell 
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